8-K: Avalo Therapeutics Unveils Promising AVTX-009 Data and $10B+ Hidradenitis Suppurativa Market Opportunity

Avalo Therapeutics, Inc. (AVTX) has released an updated investor presentation highlighting its lead compound AVTX-009 for hidradenitis suppurativa (HS) and projecting a significant market opportunity with a cash runway into at least 2027.

Summary

• Avalo Therapeutics (AVTX) has posted an updated investor presentation focusing on its lead compound, AVTX-009, an anti-IL-1 monoclonal antibody.
• AVTX-009 is being developed for hidradenitis suppurativa (HS) and aims for a 'best-in-disease' profile, targeting IL-1α as a dominant immunoregulator in HS.
• The HS market is projected to grow to over $10 billion by 2035, driven by increased diagnosis and treatment rates.
• The Phase 2 LOTUS trial for AVTX-009 in HS has been initiated, with topline data expected in mid-2026.
• Avalo Therapeutics reports approximately $125 million in cash as of March 31, 2025, providing an expected cash runway into at least 2027.
• AVTX-009 demonstrates 15x higher affinity and a longer half-life (19 days) compared to lutikizumab, potentially leading to higher efficacy and more convenient dosing.
• As of March 31, 2025, the company had 10.8 million common shares outstanding and 24.7 million preferred stock, resulting in an adjusted common share count of 35.5 million and an adjusted market capitalization of $284.5 million at a stock price of $8.01.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook, emphasizing a promising lead drug candidate (AVTX-009) with superior characteristics, a large and growing target market (HS), a strong cash position providing extended runway, and an experienced management team. The clear articulation of future milestones further contributes to the positive sentiment.

Positives

• Lead compound AVTX-009 has the potential for a 'best-in-disease' profile in hidradenitis suppurativa (HS).
• The HS market is expected to grow significantly to over $10 billion by 2035, indicating a large addressable market.
• Avalo Therapeutics has an expected cash runway into at least 2027, providing financial stability for ongoing operations and trials.
• AVTX-009 exhibits superior pharmacological properties, including 15x higher affinity and a longer half-life (19 days) than lutikizumab, suggesting potential for higher efficacy and less frequent dosing (up to Q4W).
• Preclinical and clinical evidence supports IL-1α as a dominant immunoregulator in HS, which AVTX-009 specifically targets.
• The management team possesses over 200 years of combined experience in biotech and pharma, indicating strong leadership.
• AVTX-009 has a well-tolerated and favorable safety profile demonstrated in previous Phase 1 and Phase 2 trials involving 245 patients.
• The company is assessing broad potential for indication expansion beyond HS, including other arthritis indications and inflammatory bowel disease, based on IL-1's role in inflammation.

Risks

• Risks associated with the integration of AVTX-009 into Avalo's operations.
• Uncertainties regarding drug development costs, timing of trial results, and reliance on investigators and patient enrollment in clinical trials.
• Risks related to the intended use of proceeds from the private placement.
• Reliance on key personnel for continued operations and success.
• Regulatory risks inherent in the pharmaceutical development process.
• General economic and market risks and uncertainties, including those caused by geopolitical events such as the war in Ukraine and the Middle East.
• Other risks detailed in Avalo's filings with the Securities and Exchange Commission.

Future Outlook

Avalo Therapeutics anticipates topline data from its Phase 2 LOTUS trial for AVTX-009 in hidradenitis suppurativa by mid-2026. Following a successful readout, the company plans to initiate a pivotal program in 2027. The overall hidradenitis suppurativa market is projected to grow significantly to over $10 billion by 2035, driven by increasing diagnosis rates and new treatment approvals. Avalo is also actively assessing additional immunology indications for future investment, leveraging the broad potential of IL-1 targeting therapies.

Management Comments

• Avalo Therapeutics is focused on 'Developing Targeted Therapies for Immune Mediated Inflammatory Diseases'.
• The company expects to have 'cash runway into at least 2027'.

Industry Context

Hidradenitis Suppurativa (HS) is a chronic, debilitating inflammatory skin disease with a significant unmet medical need, as a majority of patients do not respond adequately to current anti-TNF and anti-IL-17 biologics. The document positions AVTX-009 as a potential 'best-in-disease' therapy by specifically targeting IL-1α, which is identified as a dominant immunoregulator in HS. This approach aims to address the limitations of existing treatments and capitalize on the projected growth of the HS market to over $10 billion by 2035, driven by increased disease recognition and treatment adoption.

Comparison to Industry Standards

• **Lutikizumab (AbbVie, IL-1α/β)**: While lutikizumab demonstrated comparable efficacy to market leaders in a refractory HS population, AVTX-009 is highlighted for its superior properties, including 15x higher affinity for IL-1 and a longer half-life (19 days vs. 10-14 days). This suggests AVTX-009 could offer higher efficacy and more convenient dosing (potentially Q4W vs. Q1W/Q2W for lutikizumab).
• **Bimekizumab (IL-17A/F inhibitor)**: Phase 3 BE HEARD I and II trials showed HiSCR75 rates of 45.9% and 45.2% respectively at 16 weeks. AVTX-009 targets IL-1, which is upstream of IL-17, potentially offering a more foundational approach to inflammation in HS.
• **Povorcitinib (JAK1 inhibitor)**: A Phase 2 trial reported HiSCR75 rates of 37.8% (75mg QD) and 39.2% (45mg QD) at 16 weeks. AVTX-009's mechanism of action is distinct from JAK inhibition, focusing on a specific cytokine pathway.
• **Adalimumab (TNF inhibitor)**: Used as a comparator in some studies, with Bermekimab (an IL-1β specific mAb) performing no better than placebo against it. This underscores the challenge of current therapies and the potential for a more targeted IL-1α approach like AVTX-009.
• **Bermekimab (IL-1β specific mAb)**: Performed no better than placebo in a Phase 2 study. This contrasts with AVTX-009's focus on IL-1α, which the document argues is the predominant IL-1 isoform driving chronic inflammation in HS, suggesting a more effective target for HS treatment.

Stakeholder Impact

• **Shareholders**: Potential for significant value appreciation if AVTX-009 successfully progresses through clinical trials and achieves commercialization in the large HS market, supported by the company's extended cash runway.
• **Patients**: Offers hope for a potentially more effective and convenient treatment option for Hidradenitis Suppurativa, addressing a high unmet medical need.
• **Employees**: Provides stability and potential growth opportunities within the company as it advances its lead program and explores new indications.

Next Steps

• First patient enrolled in Phase 2 LOTUS trial (October 2024).
• Topline data readout from the Phase 2 LOTUS trial (Mid-2026).
• Initiate pivotal program for AVTX-009 (2027, pending Phase 2 readout).
• Assess additional immunology indications for investment to expand AVTX-009's therapeutic reach.

Key Dates

Recommendation

Keywords

Avalo Therapeutics, AVTX, AVTX-009, Hidradenitis Suppurativa, HS, IL-1, Monoclonal Antibody, mAb, LOTUS trial, Biopharmaceutical, Clinical Trials, Immunology, Inflammatory Diseases, Drug Development, Biologics